Article Text

PDF
1-Hexyl n-cyanoacrylate compound (Neucrylate™ AN), a new treatment for berry aneurysm. III: Initial clinical results
  1. R S Pakbaz1,
  2. M Shakiba2,
  3. H Ghanaati2,
  4. S Akhlaghpoor2,
  5. A Shakourirad2,
  6. C W Kerber1
  1. 1Department of Neurosurgery, UCSD Medical Centre, San Diego, CA, USA
  2. 2Department of Radiology, Imam Khomeni Hospital, Tehran, Iran
  1. Correspondence to Professor C W Kerber, Department of Neurosurgery, UCSD Medical Centre, 4444 Topa Topa Drive, La Mesa, California, 91941–7160, USA; cwkerber{at}gmail.com

Abstract

Introduction As part of an institutionally approved research protocol, patients with cerebral berry aneurysm were enrolled in a clinical trial designed to evaluate the safety of the new moldable liquid embolic agent Neucrylate AN.

Methods Twelve patients with aneurysms judged to be suboptimal for treatment by standard endovascular or surgical approaches were treated with Neucrylate AN. The agent was injected during temporary balloon occlusion at the neck of the aneurysm. The immediate angiographic percentage of aneurysm occlusion and periprocedural adverse events were assessed for each patient. Six-month follow-up angiographic studies were obtained for nine of the 12 patients.

Results Ten of the 12 aneurysms treated (83%) were large to giant (>1.0 cm in diameter), nine (75%) were wide-necked (dome/neck ratio <2.0) and three (25%) were dissecting aneurysms. There were four (33%) periprocedural neurological events. Immediate aneurysm occlusion of >90% was obtained in nine of the 12 cases (75%). There were five recurrences (55.5%) at 6 months.

Conclusion This preliminary clinical series shows that it is feasible to achieve a high percentage of immediate aneurysm occlusion with limited patient morbidity and mortality in the setting of morphologically challenging aneurysms. These preliminary data support larger trials assessing the safety and efficacy of this agent.

Statistics from Altmetric.com

Footnotes

  • Linked article 004317.

  • Competing interests CWK is a shareholder and Chief Medical Officer in Valor Medical Inc. RSP is a shareholder in Valor Medical Inc. The other authors have no competing interests.

  • Ethics approval This study was conducted with the approval of the University of Tehran.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles